['type 1 diabetes mellitus']
['placebo', 'sotagliflozin']

        Inclusion Criteria:

          -  Participant had given written informed consent to participate in the study in
             accordance with local regulations.

          -  Adult participants 18 years and older with a diagnosis of type 1 diabetes mellitus
             (T1D) made at least 1 year prior to informed consent.

          -  Participants were being treated with insulin or insulin analog delivered via
             continuous subcutaneous insulin infusion (CSII) or multiple daily injection (MDI).

          -  At the Screening Visit, A1C had to be between 7.0% and 10.0%.

          -  Females of childbearing potential had to use an adequate method of contraception and
             have a negative pregnancy test.

        Exclusion Criteria:

          -  Use of antidiabetic agent other than insulin or insulin analog at the time of
             screening.

          -  Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to
             screening.

          -  Chronic systemic corticosteroid use.

          -  Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the
             Investigator.
      